Lv41
540 积分 2021-11-08 加入
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
3小时前
待确认
Neoadjuvant versus Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small Cell Lung Cancer
4个月前
已完结
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer
5个月前
已完结
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)
5个月前
已完结
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
5个月前
已完结
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
5个月前
已完结
Finding One Treatment for All Advanced EGFR-positive NSCLC—An Infinite Task
5个月前
已完结
Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision
5个月前
已完结
Management of locally advanced non‐small cell lung cancer: state of the art and future directions
5个月前
已完结
Liquid biopsy for the management of NSCLC patients under osimertinib treatment
5个月前
已完结
皖公网安备34019202002308
